Lexicon Pharmaceuticals (LXRX) Profit After Tax (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Profit After Tax of -$1.2 million for Q1 2026, up 95.24% year-over-year from -$616151.7 in Q1 2025, and up 92.3% quarter-over-quarter from -$15.6 million in Q4 2025.
Powered by 
Analysis
Lexicon Pharmaceuticals (LXRX) Profit After Tax (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Profit After Tax for 17 consecutive years, with -$1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 95.24% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at -$26.3 million (up 85.09% YoY), while the FY2025 annual figure was -$50.4 million, up 74.82% from the prior year.
- Profit After Tax improved to -$1.2 million in Q1 2026 per LXRX's latest filing, from -$15.6 million in the prior quarter.
- Across five years, Profit After Tax topped out at $3.3 million in Q2 2025 and bottomed at -$64.3 million in Q3 2024.
- Historically, Profit After Tax has averaged -$31.2 million across 5 years, with a median of -$30.0 million in 2022.
- Annual changes were most pronounced in 2023 — Profit After Tax sank 112.99% — and 2025, when it jumped 106.09%.
- Lexicon Pharmaceuticals' Profit After Tax stood at -$30.0 million in 2022, then sank by 64.25% to -$49.3 million in 2023, then jumped by 31.68% to -$33.7 million in 2024, then surged by 53.62% to -$15.6 million in 2025, then surged by 92.3% to -$1.2 million in 2026.
- Business Quant data shows LXRX's Profit After Tax at -$1.2 million in Q1 2026, -$15.6 million in Q4 2025, and -$12.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Lexicon Pharmaceuticals | 978.15 Mn | 787.54 Mn | 653,000.00 | -31.85 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -31.85 Mn |
| Mar 31, 2026 | -1.04 Mn |
| Dec 31, 2025 | -15.53 Mn |
| Sep 30, 2025 | -12.77 Mn |
| Jun 30, 2025 | 3.25 Mn |
| Mar 31, 2025 | -25.30 Mn |
| Dec 31, 2024 | -33.77 Mn |
| Sep 30, 2024 | -64.81 Mn |
| Jun 30, 2024 | -53.43 Mn |
| Mar 31, 2024 | -48.40 Mn |
| Dec 31, 2023 | -49.76 Mn |
| Sep 30, 2023 | -50.54 Mn |
| Jun 30, 2023 | -44.90 Mn |
| Mar 31, 2023 | -31.93 Mn |
| Dec 31, 2022 | -30.43 Mn |
| Sep 30, 2022 | -23.73 Mn |
| Jun 30, 2022 | -24.59 Mn |
| Mar 31, 2022 | -23.48 Mn |
| Dec 31, 2021 | -25.62 Mn |
| Sep 30, 2021 | -23.12 Mn |